--- title: "Verrica To Present Positive Phase 2 Data For VP-315 In Treating Basal Cell Carcinoma At SID Meeting" type: "News" locale: "en" url: "https://longbridge.com/en/news/285349672.md" description: "Verrica Therapeutics Inc. (VRCA) announced positive Phase 2 data for VP-315, an oncolytic peptide immunotherapy for basal cell carcinoma (BCC), at the Society for Investigative Dermatology meeting. The study showed an abscopal effect, with non-treated lesions reducing in size by 67% and 21% achieving complete histological clearance. VP-315 offers a non-surgical treatment option for BCC and is also being investigated for other cancers. VRCA's stock rose 12.58% to $7.16, with after-hours trading at $7.20, up 0.56%." datetime: "2026-05-06T09:50:16.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285349672.md) - [en](https://longbridge.com/en/news/285349672.md) - [zh-HK](https://longbridge.com/zh-HK/news/285349672.md) generator: "portal-rs" --- # Verrica To Present Positive Phase 2 Data For VP-315 In Treating Basal Cell Carcinoma At SID Meeting (RTTNews) - Verrica Therapeutics Inc. (VRCA), a dermatology therapeutics company, on Tuesday announced the presentation of Phase 2 data indicating an abscopal effect for VP-315 in treating basal cell carcinoma at the Society for Investigative Dermatology (SID) annual meeting on May 15, 2026. Basal cell carcinoma (BCC) is a type of skin cancer that is the most common cancer form in the U.S., with 36 million new cases diagnosed every year. Causing multiple tumors and cancerous lesions, BCC is often treated with surgical excisions, which can lead to scarring, bleeding, and infection. The company developed VP-315 as a novel, oncolytic peptide immunotherapy administered directly to tumors. The drug induces immunogenic cell death by targeting a broad spectrum of tumor antigens for T-cell responses, thus providing a non-surgical option for patients with BCC. In the Phase 2 open-label study of VP-315, an abscopal effect was observed, which involves localized treatment in a patient's body triggering a therapeutic effect in distant malignancies. Patients were treated with an intratumoral injection of VP-315 in two treated lesions (TLs). Up to three non-treated lesions (NTLs) per subject were also monitored over 12 weeks. The NTLs exhibited a 67% reduction in size, and 21% of NTLs showed complete histological clearance. This suggests that VP-315 sets off an abscopal effect, brought about by broader immune activation within the tumor microenvironment of remote NTLs. VP-315 is also being explored for various oncological indications, including non-metastatic melanoma, non-metastatic merkel cell carcinoma, and squamous cell carcinoma, and has shown positive tumor-specific immune cell responses in multi-indication Phase 1/2 oncological trials. VRCA closed Tuesday at $7.16, up 12.58%. In after-hours, shares are trading at $7.20, up 0.56%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [VRCA.US](https://longbridge.com/en/quote/VRCA.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md) ## Related News & Research - [Verrica Interim CFO John J. Kirby acquires $24,650 of common shares](https://longbridge.com/en/news/296270069.md) - [Biotech Stocks Facing FDA Decision In September 2026](https://longbridge.com/en/news/297065559.md) - [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md) - [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md) - [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**